여드름 치료 시장 규모, 점유율, 성장 및 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of acne treatment Market

The global acne treatment market was valued at USD 12.19 billion in 2025 and is projected to grow to USD 12.80 billion in 2026, reaching USD 19.55 billion by 2034, registering a CAGR of 5.40% during the forecast period. North America dominated the market in 2025, holding a 48.71% share, driven by the rising prevalence of acne, increasing aesthetic concerns, and robust product launches by leading pharmaceutical companies.

Overview of Acne and Its Treatments

Acne is a common skin condition caused when hair follicles become clogged with dead skin cells and oil. While it primarily affects teenagers, it also impacts adults. Treatments vary according to severity, often requiring antibiotics, retinoids, and retinoid-like drugs, with treatment durations spanning several months. The growing prevalence of skin disorders globally is a significant driver for the acne treatment market. For instance, the National Center for Biotechnology Information (NCBI) reported that 9.4% of the global population was affected by acne in 2022, making it the eighth most prevalent disease worldwide.

The COVID-19 pandemic temporarily reduced patient visits for acne treatment in 2020. However, in 2021, as restrictions eased, patient consultations rose, further supported by the surge in mask-induced acne cases.

Key Market Drivers

The increasing prevalence of acne globally is a primary factor propelling market growth. In the U.S. alone, over 50 million people suffered from acne in 2022, highlighting the expanding patient pool in North America, Europe, and Asia Pacific. Awareness campaigns and product innovation have further fueled demand. For example, in June 2021, Dermalogica launched a campaign promoting acne awareness and skin acceptance.

Novel drug launches have also contributed to market expansion. In October 2023, the U.S. FDA approved IDP-126 (Cabtreo), a triple-combination topical treatment by Bausch Health. Other notable launches include Glenmark Pharmaceuticals' MINYM Gel in India and Bausch Health's ARAZLO lotion in the U.S., reflecting ongoing innovation in acne therapeutics.

Market Restraints

Despite growth, side effects of current drugs limit market adoption. Common reactions to antibiotics, such as nausea or diarrhea, affect 4-7% of patients. The risk of antibiotic resistance, reported in over 2.8 million U.S. cases by the CDC, further restricts widespread use. Additionally, certain OTC drugs carry warnings from the FDA regarding severe allergic reactions.

Market Segmentation

By Product Type:

• Antibiotics dominated with a 46.16% market share in 2026, due to high efficacy and continuous clinical approvals.
• Retinoids are projected to achieve higher CAGR by 2034, driven by moderate-to-severe acne cases.
• Isotretinoin and other products complement the portfolio but hold smaller shares.

By Route of Administration:

• Topical treatments held 63.42% share in 2026, reflecting patient preference for OTC and convenient applications.
• Oral treatments are expected to grow steadily due to rising incidence and product launches like Almirall's Seysara in 2019.

By Age Group:

• The 18-44 years segment dominated with 55.14% share in 2026, reflecting the increasing adult acne population.
• Teenagers (10-17 years) also show significant growth due to high acne prevalence.

By Distribution Channel:

• Retail & online pharmacies captured 94.19% market share in 2026, driven by platforms such as Amazon and Walmart, and rising OTC demand.
• Hospital pharmacies remain important for prescription-based treatments.

Regional Insights

• North America: Market value of USD 5.70 billion in 2024, projected U.S. market reaching USD 6.05 billion by 2026, driven by R&D investments, dermatology consultations, and advanced treatment awareness.
• Europe: Strong R&D and adoption of advanced treatments place it second, with UK at USD 0.52 billion and Germany at USD 0.61 billion by 2026.
• Asia Pacific: Expected highest CAGR due to rising awareness and pharmaceutical expansion. Markets like Japan, China, and India are projected at USD 0.54B, 0.63B, and 0.67B respectively by 2026.
• Latin America and Middle East & Africa: Stable growth, with MEA holding a smaller share due to emerging market conditions.

Competitive Landscape

The acne treatment market features major players with diversified portfolios. Leading companies include AbbVie Inc., Botanix Pharmaceuticals, Galderma S.A., Bausch Health Companies Inc., GlaxoSmithKline Plc., Bayer AG, Johnson & Johnson, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. Notable recent developments:

• October 2023: tbh Skincare partnered with Coles in Australia.
• December 2022: Beiersdorf AG acquired Belgium's S-Biomedic NV.
• March 2022: Galderma launched Twyneo in the U.S.
• January 2022: GALDERMA acquired ALASTIN Skincare for physician-dispensed skincare products.

Conclusion

The global acne treatment market is poised for steady growth from USD 12.19 billion in 2025 to USD 19.55 billion by 2034, driven by rising prevalence, product innovation, and expanding awareness. North America continues to dominate, while Asia Pacific shows the highest growth potential. Despite challenges like drug side effects and antibiotic resistance, the market outlook remains promising due to novel therapies, increasing patient awareness, and strategic expansion by key players.

Segmentation By Product

• Retinoids
• Antibiotics
• Isotretinoin
• Others

By Route of Administration

• Oral
• Topical

By Age Group

• 10 to 17 Years
• 18 to 44 Years
• 45 to 64 Years
• 65 Years & Above

By Distribution Channel

• Hospital Pharmacies
• Retail & Online Pharmacies

By Geography

• North America (By Product, By Route of Administration, By Age Group, By Distribution Channel, and By Country)
  • U.S. (By Product)
  • Canada (By Product)
• Europe (By Product, By Route of Administration, By Age Group, By Distribution Channel, and By Country)
  • U.K. (By Product)
  • Germany (By Product)
  • France (By Product)
  • Italy (By Product)
  • Spain (By Product)
  • Rest of Europe (By Product)
• Asia Pacific (By Product, By Route of Administration, By Age Group, By Distribution Channel, and By Country)
  • China (By Product)
  • Japan (By Product)
  • India (By Product)
  • Australia (By Product)
  • Southeast Asia (By Product)
  • Rest of Asia Pacific (By Product)
• Latin America (By Product, By Route of Administration, By Age Group, By Distribution Channel, and By Country)
  • Brazil (By Product)
  • Mexico (By Product)
  • Rest of Latin America (By Product)
• Middle East & Africa (By Product, By Route of Administration, By Age Group, By Distribution Channel, and By Country)
  • GCC (By Product)
  • South Africa (By Product)
  • Rest of MEA (By Product)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Acne, By Key Region/ Country, 2025
• 4.2. New Product Launches, By Key Players
• 4.3. Pipeline Analysis, for Key Players
• 4.4. Key Industry Developments - Mergers, Acquisitions, etc.
• 4.5. Impact of COVID-19 on the Market

5. Global Acne Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. Retinoids
  • 5.1.2. Antibiotics
  • 5.1.3. Isotretinoin
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.2.1. Oral
  • 5.2.2. Topical
• 5.3. Market Analysis, Insights and Forecast - By Age Group
  • 5.3.1. 10 to 17 Years
  • 5.3.2. 18 to 44 Years
  • 5.3.3. 45 to 64 Years
  • 5.3.4. 65 Years & Above
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Retail & Online Pharmacies
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Acne Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. Retinoids
  • 6.1.2. Antibiotics
  • 6.1.3. Isotretinoin
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.2.1. Oral
  • 6.2.2. Topical
• 6.3. Market Analysis, Insights and Forecast - By Age Group
  • 6.3.1. 10 to 17 Years
  • 6.3.2. 18 to 44 Years
  • 6.3.3. 45 to 64 Years
  • 6.3.4. 65 Years & Above
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacies
  • 6.4.2. Retail & Online Pharmacies
• 6.5. Market Analysis, Insights and Forecast - By Country / Sub-region
  • 6.5.1. U.S.
    • 6.5.1.1. By Product
  • 6.5.2. Canada
    • 6.5.2.1. By Product

7. Europe Acne Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. Retinoids
  • 7.1.2. Antibiotics
  • 7.1.3. Isotretinoin
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.2.1. Oral
  • 7.2.2. Topical
• 7.3. Market Analysis, Insights and Forecast - By Age Group
  • 7.3.1. 10 to 17 Years
  • 7.3.2. 18 to 44 Years
  • 7.3.3. 45 to 64 Years
  • 7.3.4. 65 Years & Above
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Retail & Online Pharmacies
• 7.5. Market Analysis, Insights and Forecast - By Country / Sub-region
  • 7.5.1. Germany
    • 7.5.1.1. By Product
  • 7.5.2. U.K.
    • 7.5.2.1. By Product
  • 7.5.3. France
    • 7.5.3.1. By Product
  • 7.5.4. Italy
    • 7.5.4.1. By Product
  • 7.5.5. Spain
    • 7.5.5.1. By Product
  • 7.5.6. Scandinavia
    • 7.5.6.1. By Product
  • 7.5.7. Rest of Europe
    • 7.5.7.1. By Product

8. Asia Pacific Acne Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. Retinoids
  • 8.1.2. Antibiotics
  • 8.1.3. Isotretinoin
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.2.1. Oral
  • 8.2.2. Topical
• 8.3. Market Analysis, Insights and Forecast - By Age Group
  • 8.3.1. 10 to 17 Years
  • 8.3.2. 18 to 44 Years
  • 8.3.3. 45 to 64 Years
  • 8.3.4. 65 Years & Above
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Retail & Online Pharmacies
• 8.5. Market Analysis, Insights and Forecast - By Country / Sub-region
  • 8.5.1. China
    • 8.5.1.1. By Product
  • 8.5.2. India
    • 8.5.2.1. By Product
  • 8.5.3. Japan
    • 8.5.3.1. By Product
  • 8.5.4. Australia
    • 8.5.4.1. By Product
  • 8.5.5. Southeast Asia
    • 8.5.5.1. By Product
  • 8.5.6. Rest of Asia Pacific
    • 8.5.6.1. By Product

9. Latin America Acne Treatment Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. Retinoids
  • 9.1.2. Antibiotics
  • 9.1.3. Isotretinoin
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.2.1. Oral
  • 9.2.2. Topical
• 9.3. Market Analysis, Insights and Forecast - By Age Group
  • 9.3.1. 10 to 17 Years
  • 9.3.2. 18 to 44 Years
  • 9.3.3. 45 to 64 Years
  • 9.3.4. 65 Years & Above
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Retail & Online Pharmacies
• 9.5. Market Analysis, Insights and Forecast - By Country / Sub-region
  • 9.5.1. Brazil
    • 9.5.1.1. By Product
  • 9.5.2. Mexico
    • 9.5.2.1. By Product
  • 9.5.3. Rest of Latin America
    • 9.5.3.1. By Product

10. Middle East & Africa Acne Treatment Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product
  • 10.1.1. Retinoids
  • 10.1.2. Antibiotics
  • 10.1.3. Isotretinoin
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.2.1. Oral
  • 10.2.2. Topical
• 10.3. Market Analysis, Insights and Forecast - By Age Group
  • 10.3.1. 10 to 17 Years
  • 10.3.2. 18 to 44 Years
  • 10.3.3. 45 to 64 Years
  • 10.3.4. 65 Years & Above
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Retail & Online Pharmacies
• 10.5. Market Analysis, Insights and Forecast - By Country / Sub-region
  • 10.5.1. GCC
    • 10.5.1.1. By Product
  • 10.5.2. South Africa
    • 10.5.2.1. By Product
  • 10.5.3. Rest of Middle East & Africa
    • 10.5.3.1. By Product

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. AbbVie, Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (based on availability)
  • 11.2.2. Botanix Pharmaceuticals
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (based on availability)
  • 11.2.3. GALDERMA
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (based on availability)
  • 11.2.4. Bausch Health Companies Inc.
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (based on availability)
  • 11.2.5. GlaxoSmithKline Plc
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (based on availability)
  • 11.2.6. Bayer AG
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (based on availability)
  • 11.2.7. Johnson & Johnson Services Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (based on availability)
  • 11.2.8. Pfizer
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (based on availability)
  • 11.2.9. Teva Pharmaceutical Industries Ltd
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (based on availability)